Company

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma
Clinical trial approval / initiationHKG: 1877

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877; SHA: 688180) announced that first patient dosing has been completed in the multi‑center, randomized, controlled, open‑label Phase III JS207‑017‑III‑HCC study (NCT07823348), evaluating JS207…

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Cereblink TechnologyInnovative Medical Management

Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories
DiabetesHKG: 2552

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

AbbVie's SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
AbbVieAuto-immune

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval
Akeso BiopharmaHKG: 9926

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Show More